CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
5'-Nucleotidase
/ antagonists & inhibitors
Adenosine
/ metabolism
Animals
Biomarkers, Tumor
/ blood
Brain Neoplasms
/ blood
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ genetics
Cell Survival
Disease Progression
Down-Regulation
/ genetics
Gene Knockdown Techniques
Glioblastoma
/ blood
Humans
Matrix Metalloproteinase 2
/ metabolism
NF-kappa B
/ metabolism
Neoplasm Invasiveness
Proto-Oncogene Proteins c-akt
/ metabolism
Rats
Receptors, Purinergic P1
/ metabolism
Signal Transduction
Temozolomide
/ pharmacology
Vimentin
/ metabolism
APCP
Adenosine
CD73
Glioma
siRNA
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
28
03
2018
accepted:
11
07
2018
pubmed:
18
8
2018
medline:
21
8
2019
entrez:
18
8
2018
Statut:
ppublish
Résumé
Glioblastoma is the worst and most common primary brain tumor. Here, we demonstrated the role of CD73, an enzyme responsible for adenosine (ADO) production, in glioblastoma progression. ADO increased glioma cell viability via A1 receptor sensitization. CD73 downregulation decreased glioma cell migration and invasion by reducing metalloproteinase-2 and vimentin expression and reduced cell proliferation by 40%, which was related to necrosis and sub-G1 phase blockage of cell cycle. Those effects also involved the stimulation of Akt/NF-kB pathways. Additionally, CD73 knockdown or enzyme inhibition potentiated temozolomide cytotoxic effect on glioma cells by decreasing the IC
Identifiants
pubmed: 30117104
doi: 10.1007/s12035-018-1240-4
pii: 10.1007/s12035-018-1240-4
doi:
Substances chimiques
Biomarkers, Tumor
0
NF-kappa B
0
Receptors, Purinergic P1
0
Vimentin
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
5'-Nucleotidase
EC 3.1.3.5
Matrix Metalloproteinase 2
EC 3.4.24.24
Adenosine
K72T3FS567
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Pagination
3260-3279Références
Anticancer Res. 1999 May-Jun;19(3A):1747-52
pubmed: 10470109
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Immunol. 2002 Mar;3(3):221-7
pubmed: 11875461
Brain Res. 2002 Sep 20;950(1-2):74-8
pubmed: 12231230
Cancer Lett. 2003 Aug 20;198(2):211-8
pubmed: 12957360
J Neurooncol. 2003 Sep;64(3):211-8
pubmed: 14558596
Curr Neurol Neurosci Rep. 2005 May;5(3):198-206
pubmed: 15865885
BMC Cancer. 2006 Sep 23;6:226
pubmed: 16995949
Eur J Pharmacol. 2007 Aug 13;569(1-2):8-15
pubmed: 17568578
Clin Exp Metastasis. 2007;24(6):439-48
pubmed: 17587186
J Immunol. 2008 Jul 1;181(1):464-75
pubmed: 18566412
Mol Cell Biochem. 2008 Dec;319(1-2):61-8
pubmed: 18636315
Cell Tissue Res. 2009 Feb;335(2):331-40
pubmed: 19023597
Purinergic Signal. 2009 Sep;5(3):273-5
pubmed: 19322680
Cancer Sci. 2009 Aug;100(8):1434-42
pubmed: 19558578
Mol Cell Biochem. 2012 Jan;359(1-2):315-22
pubmed: 21858682
Purinergic Signal. 2012 Sep;8(3):437-502
pubmed: 22555564
J Cell Physiol. 2013 Mar;228(3):602-8
pubmed: 22833450
Neurochem Res. 2012 Dec;37(12):2667-77
pubmed: 22878643
Adv Exp Med Biol. 2013;986:13-30
pubmed: 22879062
J Biomed Biotechnol. 2012;2012:485156
pubmed: 23125525
Neuro Oncol. 2013 Sep;15(9):1160-72
pubmed: 23737488
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6
pubmed: 23776241
Epilepsia. 2013 Sep;54 Suppl 6:20-2
pubmed: 24001064
Int J Biochem Cell Biol. 2014 Apr;49:8-16
pubmed: 24434023
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
Biochim Biophys Acta. 2015 Jan;1852(1):120-30
pubmed: 25445541
Cancer Lett. 2015 Mar 28;358(2):220-231
pubmed: 25542083
PLoS One. 2015 Mar 18;10(3):e0118864
pubmed: 25785932
Cell Tissue Res. 2015 Oct;362(1):45-60
pubmed: 25948484
Oncol Lett. 2015 Jul;10(1):342-348
pubmed: 26171027
PLoS One. 2015 Aug 11;10(8):e0134934
pubmed: 26263491
Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3201-7
pubmed: 26400523
Neuro Oncol. 2016 Mar;18(3):329-39
pubmed: 26534766
Int J Biochem Cell Biol. 2015 Dec;69:1-10
pubmed: 26545615
Mol Neurobiol. 2016 Dec;53(10):7184-7199
pubmed: 26687184
Curr Opin Pharmacol. 2016 Aug;29:7-16
pubmed: 27209048
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
Neurochem Res. 2017 Mar;42(3):918-924
pubmed: 27568206
Oncotarget. 2016 Oct 11;7(41):67373-67386
pubmed: 27634913
Tumour Biol. 2016 Nov;37(11):15333-15339
pubmed: 27704357
Cancer Lett. 2017 Apr 1;390:176-187
pubmed: 28007636
Chem Biol Interact. 2017 Mar 25;266:1-9
pubmed: 28174097
Mol Aspects Med. 2017 Jun;55:140-151
pubmed: 28223127
J Cell Physiol. 2018 Mar;233(3):2032-2057
pubmed: 28233320
Curr Med Chem. 2017;24(25):2781-2795
pubmed: 28260500
Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535
pubmed: 28399672
Drug Discov Today. 2017 Nov;22(11):1686-1696
pubmed: 28676406
Front Pharmacol. 2017 Sep 25;8:661
pubmed: 28993732
J Pharm Pharmacol. 2018 Feb;70(2):191-196
pubmed: 29057476
Neurosurg Rev. 2017 Nov 14;:null
pubmed: 29138949
Purinergic Signal. 2018 Mar;14(1):1-18
pubmed: 29164451
Int J Mol Sci. 2017 Nov 27;18(12):null
pubmed: 29186899
Int J Mol Sci. 2018 Jan 02;19(1):null
pubmed: 29301329
Front Pharmacol. 2018 Jan 10;8:985
pubmed: 29375384
Cancer Microenviron. 2018 Jun;11(1):61-70
pubmed: 29455338
Anal Biochem. 1986 Sep;157(2):375-80
pubmed: 2946250
Oncol Lett. 2018 Jun;15(6):9377-9384
pubmed: 29928334
Cell Biol Int. 2019 Feb;43(2):98-107
pubmed: 29972257
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051